

Docket No.: C2432.0060  
(PATENT)

Express Mail Label No.: EV 262 741 419 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Bengt Herslöf et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: ANTICOAGULANT COMPOSITION

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

**Timing of Filing of the Information Disclosure Statement:**

☒ This IDS is being filed before the First Office Action<sup>1</sup>.

**Copies of Information:**

☒ Copies of the cited ISR documents are not enclosed as they were provided by the International Bureau.

<sup>1</sup> The IDS should, where possible, include a certification under 37 C.F.R. §1.97(e).

Application No.: Not Yet Assigned

Docket No.: C2432.0060  
 Express Mail Label No.: EV 262 741 419 US

**Materiality:**

Whether or not the information and references disclosed in this Information Disclosure Statement is "material" pursuant to 37 CFR 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

In the event the actual fee is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 50-2215.

Dated: December 3, 2004

Respectfully submitted,

By Edward A. Meilman  
 Edward A. Meilman  
 Registration No.: 24,735  
 DICKSTEIN SHAPIRO MORIN &  
 OSHINSKY LLP  
 1177 Avenue of the Americas  
 New York, New York 10036-2714  
 (212) 835-1400  
 Attorney for Applicant

EAM/da

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Bengt Herslöf
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	C2432.0060

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,626,869	05-06-1997	Nyqvist Hakan, et al.	
	AB	US-5,082,667	01-21-1992	Kurt G. Van Scoik	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					
	BA	WO-92/05771-A1		04-16-1992	KABI PHARMACIA AB		
	BB	EP-0368247-A2		05-16-1990	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	BC	WO-03/49721-A1		06-19-2003	COSMO S.P.A.		
	BD	WO-02/47663-A1		06-20-2002	F. HOFFMAN-LA ROCHE AG		
	BE	WO-01/91729-A1		12-06-2001	BASF AKTIENGESELLSCHAFT		
	BF	WO-93/19737-A1		10-14-1993	KABI PHARMACIA AB		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	European Journal of Pharmaceutical Sciences, Volume 1, 1994, L. Lohikangas et al.; "Relative contribution of phosphatidylcholine and monoglyceride to absorption enhancement of low molecular weight heparin (Fragmin) by a new lipid-based drug delivery system in monolayers of human intestinal epithelial Caco-2 cells and after rectal administration to rabbits"; pp. 307 - 312, abstract 3.1, 3.3, discussion	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--